NCT06309823View on ClinicalTrials.gov

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

January 17, 2024

Study Completion Date

January 17, 2024

Conditions
X-linked Lymphoproliferative Syndrome Type 2 (XLP-2)
Interventions
DRUG

MAS825

MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.

Trial Locations (1)

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER